Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients.

By H. Heslop, K. Slobod, M. Pule, G. Hale, A. Rousseau, Colton A. Smith, C. Bollard, Hao Liu, Meng-fen Wu, R. Rochester and 4 more. Blood, 2010

778 citations recorded by the source corpus.

Subfields: Epidemiology, Immunology, Oncology

View Paper: https://www.semanticscholar.org/paper/20b6a59a5bdce28e6d08df1d6720311db387b034

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Immunology

1. Steven G. Deeks
2. C. June

In Oncology

1. C. June
2. B. Levine
3. J. Kochenderfer
4. Jennifer N. Brudno
5. Michel Sadelain
6. Wendell A. Lim
7. S. Grupp

Citations in the corpus

• Decade-Long Safety and Function of Retroviral-Modified Chimeric Antigen Receptor T-cells (2012, background): “Similarly, in lymphopenic patients after hematopoietic stem cell transplantation, gene-marked EBV-specific cytotoxic T lymphocytes have been shown to persist for up to 9 years (5).”
• Therapeutic cancer vaccines. (2010, background): “Immunotherapy for malignant disease caused by EBV is a classical success story for adoptive transfer of EBV-specific T cells in diseases such as post-transplantation EBV-induced lymphomas (11), but therapeutic vaccination against EBV-related diseases is still relatively underdeveloped.”